|
Published by: Espicom Healthcare Intelligence
Published: Aug. 21, 2009 - 128 Pages
Table of Contents
- Foreword
- Executive Summary
- Overview
- Leading Generic Markets
- Controlled-Release Delivery Technology
- Delivery Platforms
- Controlled-Release Drugs
- FDA Approved Generics
- Cardiovascular
- Lescol XL (fluvastatin)
- Patents & Exclusivity
- Generic Company Activity
- Advicor (lovastatin+niacin)
- Patents
- Generic Company Activity
- Coreg CR (carvedilol phosphate)
- Patents & Exclusivity
- Generic Company Activity
- Cardizem LA (diltiazem)
- Patents
- Generic Company Activity
- Seloken/Toprol-XL (metoprolol succinate)
- Generics
- Orbus Pharma
- Adalat CC (nifedipine)
- Patents
- Generic Company Activity
- Tarka (trandolapril+verapamil)
- Patents
- Generic Company Activity
- Aggrenox (dypyridamole+acetylsalicylic acid)
- Patents
- Generic Company Activity
- CNS
- Concerta (methylphenidate)
- Patents
- Generic Company Activity
- Andrx (Watson)
- Impax
- Metadate CD / Equasym XL (methylphenidate)
- Patents
- Generic Company Activity
- Ritalin LA (methylphenidate)
- Patents
- Generic Company Activity
- Focalin XR (dexmethylphenidate)
- Patents
- Generic Company Activity
- Adderall XR (mixed amphetamine salts)
- Patents
- Generic Company Activity
- Barr & Teva
- Impax
- Actavis & Colony Pharmaceuticals
- Sandoz
- Andrx
- Carbatrol (carbamazepine)
- Patents
- Generic Company Activity
- Impax
- Nostrum
- CorePharma
- Teva
- Apotex
- Actavis
- Equetro (carbamazepine)
- Patents
- Generic Company Activity
- Tegretol XR (carbamazepine)
- Patents
- Generic Company Activity
- Seroquel XR (quetiapine)
- Patents & Exclusivity
- Generic Company Activity
- Amrix (cyclobenzaprine)
- Patents & Exclusivity
- Generic Company Activity
- Avinza (morphine)
- Patents
- Generic Company Activity
- OxyContin (oxycodone)
- Patents
- Generic Company Activity
- KV Pharmaceutical Company
- Mallinckrodt
- Impax Laboratories
- Teva Pharmaceutical Industries
- Endo Pharmaceuticals
- Opana ER (oxymorphone)
- Patents
- Generic Company Activity
- Impax
- Actavis
- Barr (Teva)
- Ultram ER (tramadol)
- Patents
- Generic Company Activity
- Cipher Pharmaceuticals
- Impax
- Effexor XR (venlafaxine)
- Patents
- Generic Company Activity
- Osmotica
- Lupin
- Cadila Healthcare
- Torrent Pharmaceuticals
- Sun Pharma
- Anchen Pharmaceuticals
- Mylan
- Apotex
- Biovail
- Impax
- Teva Pharmaceutical Industries
- Ambien CR (zolpidem tartrate)
- Patents
- Requip XL (ropinirole)
- Patents & Exclusivity
- Generic Company Activity
- Others
- Xatral/Uroxatral (alfuzosin)
- Patents
- Generic Company Activity
- Oxytrol (oxybutynin)
- Patents
- Generic Company Activity
- Detrol LA (tolterodine)
- Patents
- Generic Company Activity
- Sanctura XR (trospium chloride)
- Patents & Exclusivity
- Generic Company Activity
- Augmentin XR (amoxicillin+clavulanic acid)
- Patents
- Company Profiles
- Actavis
- CR/ER Products
- Patent Litigation & Agreements
- Oxymorphone litigation settled
- Acquisitions
- Actavis strengthens its position in India
- Actavis acquires Abrika
- Actavis acquires Alpharma’s Human Generics business
- Financials
- Handa Pharmaceuticals
- Seroquel XR Litigation
- Impax Laboratories
- Products
- R&D
- Patent Litigation & Agreements
- Suit filed as Impax submits ANDA for generic Amrix
- Lawsuit for infringement of Renvela patents
- Lawsuit for infringement of Doryx patent
- Agreement with Teva
- Financials
- KV Pharmaceutical
- CR/ER Products
- Patent Litigation Agreement
- KV settles oxycodone litigation with Purdue Pharma
- Financials
- Mallinckrodt
- CR/ER Products
- Mylan
- Products
- Patent Litigation
- Amrix
- Effexor XR
- Uroxatral
- Acquisitions
- Merck Generics Acquisition
- Matrix Laboratories Acquisition
- Financials
- Par Pharmaceutical
- CR/ER Products
- Patent Litigation
- Par and Reliant settle propafenone litigation
- Litigation relating to tramadol extended-release tablets
- Agreements
- AstraZeneca/Par enter agreement for generic version of Toprol-XL
- IntelliPharmaCeutics announces equity investment by Par Pharmaceutical
- Agreement with Abrika (Actavis)
- Financials
- Sun Pharma
- CR/ER Products
- Financials
- Taro Pharmaceutical Industries
- CR/ER Products
- Financials
- Teva Pharmaceutical Industries
- Products
- Patent Litigation & Agreements
- Teva Launches Generic Adderall XR
- Watson files patent lawsuit against Barr for Oxytrol
- Aggrenox Litigation Settlement with Boehringer Ingelheim
- Barr and Kos Settle Advicor Patent Litigation
- Amrix Patent Infringement Lawsuit
- Focalin XR Patent Litigation
- Ritalin LA Patent Litigation
- OxyContin Settlement
- Effexor XR Agreement
- Major Developments
- Teva acquires Barr
- Financials
- URL Pharma
- CR/ER Products
- Watson Pharmaceuticals
- CR/ER Products
- Patent Litigation
- Watson files ANDA for generic Sanctura XR; Allergan files lawsuit
- Watson files Mucinex D ANDA; Reckitt Benckiser files lawsuit
- Watson files ANDA for generic Enablex; Novartis files lawsuit
- Andrx gains methylphenidate court victory
- Acquisition
- Watson completes acquisition of Andrx
- Financials
- Zydus Cadila
- CR/ER Products
- Financials
- Major Developments
- Etna Biotech Acquisition
- Majority stake in Simayla Pharmaceuticals
- Laboratorios Combix Acquisition
- SOURCES
- Espicom Sources
- Others
- List of Tables
- Controlled-Release Drug Sales, 2008 (US$ Million)
- Controlled-Release Drugs by Therapy Area
- Controlled-Release Drugs by US Patent Expiry
- FDA ANDA Approval for Extended-Release Drugs, 2005-2009 (30th June)
- Lescol XL US Patents
- Advicor US Patents
- Coreg CR Sales, 2007-2008 (£ & US$ Million)
- Coreg CR US Patents
- Cardizem US Patents
- Seloken ZOK/Toprol-XL Sales, 2004-2008 (US$ Million)
- FDA ANDA Approvals for Metoprolol Succinate
- Adalat CC Sales, 2004-2008 (EUR & US$ Million)
- Adalat CC US Patents
- FDA ANDA Approvals for Nifedipine Extended-Release Tablets
- Tarka US Patents
- Aggrenox Sales, 2004-2008 (EUR & US$ Million)
- Aggrenox US Patents
- Concerta US Patents
- Metadate CD US Patents
- Ritalin LA US Patents
- Focalin XR US Patents
- Adderall XR US Patents
- Carbatrol US Patents
- Equetra US Patents
- Tegretol US Patent
- Seroquel XR US Patents
- Amrix US Patents
- Avinza US Patent
- OxyContin US Patents
- Opana ER US Patents
- Ultram ER US Patents
- Effexor XR US Patents
- Ambien CR US Patent
- Requip XL Sales, 2008 (£ & US$ Million)
- Requip XL US Patents
- Xatral/Uroxatral Sales, 2004-2008 (EUR & US$ Million)
- Uroxatral US Patents
- Tentative ANDA Approvals for 10mg Alfuzosin Hydrochloride ER Tablets
- Oxytrol US Patents
- Detrol LA US Patents
- Sanctura Sales, 2007-2008 (US$ Million)
- Sanctura XR US Patents
- Augmentin XR US Patents
- Actavis ANDA Approvals for CR/ER Products, 2006-2009
- Actavis Financial Results, 2003-2006 (EUR & US$ Million)
- Impax Laboratories ANDA Approvals for ER Products, 2004-2009
- Impax Financial Results, 2004-2008 (US$ Million)
- KV Pharmaceutical ANDA Approvals for CR/ER Products, 2004-2009
- KV Pharmaceutical Financial Results, 2004-2008 (US$ Million)
- Mallinckrodt ANDA Approvals for CR/ER Products, 2003-2009
- Mylan ANDA Approvals for CR/ER Products, 2002-2009
- Mylan Financial Results, 2004-2008 (US$ Million)
- Par Pharmaceutical Financial Results 2004-08 (US$ Million)
- Sun Pharma ANDA Approvals for CR/ER Products
- Sun Pharma: Financial Results, 2004-2008
- Taro ANDA Approvals for CR/ER Products
- Taro Pharmaceutical Industries restatements for 2004 and 2005 (US$000s)
- Teva ANDA Approvals for CR/ER Products, 2002-2009
- Barr ANDA Approvals for CR/ER Products, 2002-2009
- Teva Financial Results, 2004-2008 (US$ Millions)
- URL Pharma ANDA Approvals for ER Products, 2004-2009
- Watson ANDA Approvals for CR/ER Products, 2002-2009
- Andrx ANDA Approvals for CR/ER Products, 2002-2009
- Watson Financial Results, 2004-2008 (US$ Million)
- Zydus ANDA Approvals for CR/ER Products, 2005-2009
- Zydus Tentative ANDA Approval for CR/ER Product
- Zydus Cadila Financial Results, 2005-2009
- List of Figures
- Generic Pharmaceutical Expenditure, 2008 (US$ billions)
- Generic Pharmaceutical Expenditure per capita, 2008 (US$)
- Generic Pharmaceutical Expenditure as % of Total, 2008
- FDA ANDA Approvals by Therapy Area 2005-2009*
- FDA ANDA Approvals by Therapy Area 2005-2009* (%)
- FDA ANDA Approvals by Company, 2005-2009 (30th June)
AbstractThis new report identifies 30 controlled-release drugs valued at US$15 billion, many of which will be losing patent protection in the medium term.
Get Full Details About This Report >>
|
|
US: 800.298.5699
Int'l: +1.240.747.3093
|
|
|
|
About MarketResearch.com
MarketResearch.com is an online aggregator selling over 300,000 market research reports,
company profiles and country profiles from over 700 research firms. Our reports will
provide you with the critical business and competitive intelligence you need for strategic planning and marketing
research. Coverage includes the US, UK, Europe, Asia and global markets.
© MarketResearch.com 2012
|
